Progesterone: A pivotal hormone at menstruation

Annals of the New York Academy of Sciences

Volumn 1221, Issue 1, 2011, Pages 88-97

  Maybin, Jacqueline A ^a   Critchley, Hilary O D ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiogenesis; Endometrium; Hypoxia; Inflammation; Prostaglandins; Repair

Indexed keywords

ESTRADIOL; LEVONORGESTREL; MATRIX METALLOPROTEINASE; PROGESTERONE;

ANGIOGENESIS; ARTICLE; CELL MATURATION; CELL PROLIFERATION; CORPUS LUTEUM; ENDOMETRIUM; HORMONAL REGULATION; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUATION; MENSTRUATION DISORDER; NONHUMAN; PROGESTERONE BLOOD LEVEL; TISSUE INJURY; TISSUE REPAIR; VASOCONSTRICTION;

EID: 79952675775     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05953.x     Document Type: Article

References (87)

1. Marbaix, E. et al 1996. Menstrual breakdown of human endometrium can be mimicked in vitro and is selectively and reversibly blocked by inhibitors of matrix metalloproteinases. Proc. Natl. Acad. Sci. U.S.A. 93: 9120-9125.
2. Lockwood, C.J. et al 1998. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology 139: 4607-4613.
3. Salamonsen, L.A. & D.E. Woolley 1999. Menstruation: induction by matrix metalloproteinases and inflammatory cells. J. Reprod. Immunol. 44: 1-27.
4. Zhang, J. & L.A. Salamonsen 2002. In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J. Clin. Endocrinol. Metab. 87: 2346-2351.
5. Rudolph-Owen, L.A. et al 1998. Matrix metalloproteinase expression in Macaca mulatta endometrium: evidence for zone-specific regulatory tissue gradients. Biol. Reprod. 59: 1349-1359.
6. Slayden, O.D. & R.M. Brenner 2006. A critical period of progesterone withdrawal precedes menstruation in macaques. Reprod. Biol. Endocrinol. 4: S6 1-10.
7. Markee, J.E. 1940. Menstruation in intraocular transplants in the rhesus monkey. Contr. Embryol. Carnegie. Instn. 28: 219-308.
8. Zhang, J. & L.A. Salamonsen 2002. Expression of hypoxia-inducible factors in human endometrium and suppression of matrix metalloproteinases under hypoxic conditions do not support a major role for hypoxia in regulating tissue breakdown at menstruation. Hum. Reprod. 17: 265-274.
9. Gaide Chevronnay, H.P. et al 2010. Ovarian steroids, mitogen-activated protein kinases, and/or aspartic proteinases cooperate to control endometrial remodeling by regulating gene expression in the stroma and glands. Endocrinology 151: 4515-4526.
10. Critchley, H.O. et al 2001. The endocrinology of menstruation-a role for the immune system. Clin. Endocrinol. (Oxf.). 55: 701-710.
11. Salamonsen, L.A. & L.J. Lathbury 2000. Endometrial leukocytes and menstruation. Hum. Reprod. Update. 6: 16-27.
12. Critchley, H.O. et al 1999. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J. Clin. Endocrinol. Metab. 84: 240-248.
13. Jones, R.L. et al 2004. Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. J. Clin. Endocrinol. Metab. 89: 6155-6167.
14. King, A., L. Gardner & Y.W. Loke 1996. Evaluation of oestrogen and progesterone receptor expression in uterine mucosal lymphocytes. Hum. Reprod. 11: 1079-1082.
15. Poropatich, C., M. Rojas & S.G. Silverberg 1987. Polymorphonuclear leukocytes in the endometrium during the normal menstrual cycle. Int. J. Gynecol. Pathol. 6: 230-234.
16. King, A. 2000. Uterine leukocytes and decidualization. Hum. Reprod. Update 6: 28-36.
17. Critchley, H.O., R.W. Kelly & J. Kooy 1994. Perivascular location of a chemokine interleukin-8 in human endometrium: a preliminary report. Hum. Reprod. 9: 1406-1409.
18. Jones, R.L., R.W. Kelly & H.O. Critchley 1997. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum. Reprod. 12: 1300-1306.
19. Langenbach, R. et al 1999. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem. Pharmacol. 58: 1237-1246.
20. Langenbach, R. et al 1999. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. N. Y. Acad. Sci. 889: 52-61.
21. Dinchuk, J.E. et al 1995. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409.
22. Ylikorkala, O. & U.M. Makila 1985. Prostacyclin and thromboxane in gynecology and obstetrics. Am. J. Obstet. Gynecol. 152: 318-329.
23. Williams, T.J. 1979. Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation. Br. J. Pharmacol. 65: 517-524.
24. Milne, S.A. & H.N. Jabbour 2003. Prostaglandin (PG) F(2alpha) receptor expression and signaling in human endometrium: role of PGF(2alpha) in epithelial cell proliferation. J. Clin. Endocrinol. Metab. 88: 1825-1832.
25. Milne, S.A. et al 2001. Expression, localization, and signaling of PGE(2) and EP2/EP4 receptors in human nonpregnant endometrium across the menstrual cycle. J. Clin. Endocrinol. Metab. 86: 4453-4459.
26. Colditz, I.G. 1990. Effect of exogenous prostaglandin E2 and actinomycin D on plasma leakage induced by neutrophil-activating peptide-1/interleukin-8. Immunol. Cell Biol. 68: 397-403.
27. Lessey, B.A. et al 1988. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J. Clin. Endocrinol. Metab. 67: 334-340.
28. Critchley, H.O. et al 2002. Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J. Clin. Endocrinol. Metab. 87: 5265-5273.
29. Critchley, H.O. et al 2001. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J. Clin. Endocrinol. Metab. 86: 1370-1378.
30. Lecce, G. et al 2001. Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J. Clin. Endocrinol. Metab. 86: 1379-1386.
31. Ludwig, H. & U.M. Spornitz 1991. Microarchitecture of the human endometrium by scanning electron microscopy: menstrual desquamation and remodeling. Ann. N. Y. Acad. Sci. 622: 28-46.
32. Kaitu'u-Lino, T.J., N.B. Morison & L.A. Salamonsen 2007. Estrogen is not essential for full endometrial restoration after breakdown: lessons from a mouse model. Endocrinology 148: 5105-5111.
33. Nayak, N.R. & R.M. Brenner 2002. Vascular proliferation and vascular endothelial growth factor expression in the rhesus macaque endometrium. J. Clin. Endocrinol. Metab. 87: 1845-1855.
34. Maybin, J. & H. Critchley 2009. Repair and regeneration of the human endometrium. Expert Rev. Obstet. Gynecol. 4: 283-298.
35. Salamonsen, L.A. 2003. Tissue injury and repair in the female human reproductive tract. Reproduction 125: 301-311.
36. Rae, M.T. et al 2004. Antiinflammatory steroid action in human ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 89: 4538-4544.
37. McDonald, S.E. et al 2006. 11Beta-hydroxysteroid dehydrogenases in human endometrium. Mol. Cell. Endocrinol. 248: 72-78.
38. Kim, J.P. et al 1992. Integrin receptors and RGD sequences in human keratinocyte migration: unique anti-migratory function of alpha 3 beta 1 epiligrin receptor. J. Invest. Dermatol. 98: 764-770.
39. Cao, W. et al 2007. Progesterone withdrawal up-regulates fibronectin and integrins during menstruation and repair in the rhesus macaque endometrium. Hum. Reprod. 22: 3223-3231.
40. Critchley, H.O. et al 2006. Gene expression profiling of mid to late secretory phase endometrial biopsies from women with menstrual complaint. Am. J. Obstet. Gynecol. 195: 406.e1-406.e16.
41. Sales, K.J. et al 2005. A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res. 65: 7707-7716.
42. Sales, K.J., S. Maudsley & H.N. Jabbour 2004. Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3', 5'-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Mol. Endocrinol. 18: 1533-1545.
43. Fukuda, R., B. Kelly & G.L. Semenza 2003. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63: 2330-2334.
44. Keightley, M.C. et al 2010. F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biol. 11: 81-13.
45. Sales, K.J. et al 2009. Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim. Biophys. Acta. 1793: 1917-1928.
46. Gashaw, I. et al 2008. Premenstrual regulation of the pro-angiogenic factor CYR61 in human endometrium. Endocrinology 149: 2261-2269.
47. Smith, O.P. et al 2006. Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor Receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology 147: 1697-1705.
48. Gannon, B.J., C.J. Carati & C.J. Verco 1997. Endometrial perfusion across the normal human menstrual cycle assessed by laser Doppler fluxmetry. Hum. Reprod. 12: 132-139.
49. Fan, X. et al 2008. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. Faseb. J. 22: 3571-3580.
50. Critchley, H.O. et al 2006. Hypoxia-inducible factor-1alpha expression in human endometrium and its regulation by prostaglandin E-series prostanoid receptor 2 (EP2). Endocrinology 147: 744-753.
51. Punyadeera, C. et al 2006. Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. Mol. Hum. Reprod. 12: 367-375.
52. Sivridis, E. et al 2002. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95: 1055-1063.
53. Carmeliet, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69: 4-10.
54. Nikitenko, L.L. et al 2006. Adrenomedullin and tumour angiogenesis. Br. J. Cancer 94: 1-7.
55. Hirani, N. et al 2001. The regulation of interleukin-8 by hypoxia in human macrophages-a potential role in the pathogenesis of the acute respiratory distress syndrome (ARDS). Mol. Med. 7: 685-697.
56. Nagata, D. et al 1999. Hypoxia-induced adrenomedullin production in the kidney. Kidney Int. 55: 1259-1267.
57. Gratton, R.J. et al 2003. Adrenomedullin messenger ribonucleic acid expression in the placentae of normal and preeclamptic pregnancies. J. Clin. Endocrinol. Metab. 88: 6048-6055.
58. Sharkey, A.M. et al 2000. Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. J. Clin. Endocrinol. Metab. 85: 402-409.
59. Maybin, J.A., H.O. Critchley & H.N. Jabbour 2010. Inflammatory pathways in endometrial disorders. Mol. Cell Endocrinol. Advance online publication. doi: .
60. Weiss, G. et al 2009. Inflammation in reproductive disorders. Reprod. Sci. 16: 216-229.
61. NICE. 2007. Clinical Guideline 44; Heavy menstrual bleeding. Available at: Accessed 27 January 2011.
62. Hallberg, L. et al 1966. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality. Acta Obstet. Gynecol. Scand. 45: 320-351.
63. Prentice, A. 1999. Health care implications of dysfunctional uterine bleeding. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 13: 181-188.
64. Frick, K.D. et al 2009. Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Womens Health Issues 19: 70-78.
65. Malik, S. et al 2006. Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual endometrium and effluent in women with menorrhagia. Hum. Reprod. 21: 2158-2166.
66. Smith, O.P., H.N. Jabbour & H.O. Critchley 2007. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum. Reprod. 22: 1450-1456.
67. Smith, S.K. et al 1981. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br. J. Obstet. Gynaecol. 88: 434-442.
68. Smith, S.K. et al 1981. A role for prostacyclin (PGi2) in excessive menstrual bleeding. Lancet 1: 522-524.
69. Baird, D.T. et al 1996. Prostaglandins and menstruation. Eur. J. Obstet. Gynecol. Reprod. Biol. 70: 15-17.
70. Marsh, M.M. et al 1997. Endothelin and neutral endopeptidase in the endometrium of women with menorrhagia. Hum. Reprod. 12: 2036-2040.
71. Mints, M. et al 2007. Wall discontinuities and increased expression of vascular endothelial growth factor-A and vascular endothelial growth factor receptors 1 and 2 in endometrial blood vessels of women with menorrhagia. Fertil. Steril. 88: 691-697.
72. Abberton, K.M. et al 1999. Vascular smooth muscle cell proliferation in arterioles of the human endometrium. Hum. Reprod. 14: 1072-1079.
73. Abberton, K.M., D.L. Healy & P.A. Rogers 1999. Smooth muscle alpha actin and myosin heavy chain expression in the vascular smooth muscle cells surrounding human endometrial arterioles. Hum. Reprod. 14: 3095-3100.
74. Arkonac, B.M. et al 1998. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J. Biol. Chem. 273: 4400-4405.
75. Blum, S. et al 2001. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J. Biol. Chem. 276: 33428-33434.
76. Hewett, P. et al 2002. Down-regulation of angiopoietin-1 expression in menorrhagia. Am. J. Pathol. 160: 773-780.
77. Cromwell, D.A. et al 2009. Surgery for menorrhagia within English regions: variation in rates of endometrial ablation and hysterectomy. BJOG 116: 1373-1379.
78. Weeks, A.D., S.R. Duffy & J.J. Walker 2000. A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. BJOG 107: 323-328.
79. Cameron, I.T. et al 1990. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet. Gynecol. 76: 85-88.
80. Andersson, J.K. & G. Rybo 1990. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br. J. Obstet. Gynaecol. 97: 690-694.
81. Pakarinen, P.I. et al 1998. The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel. Hum. Reprod. 13: 1846-1853.
82. Critchley, H.O. et al 1998. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 13: 1210-1217.
83. Jones, R.L. & H.O. Critchley 2000. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum. Reprod. 15: 162-172.
84. Skinner, J.L. et al 1999. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel. Hum. Reprod. 14: 793-799.
85. Vincent, A.J. et al 1999. Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9 (gelatinase B). Hum. Reprod. 14: 807-815.
86. Roopa, B.A., A. Loganath & K. Singh 2003. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Hum. Reprod. 18: 1809-1819.
87. Hickey, M. et al 2000. The measurement of endometrial perfusion in norplant users: a pilot study. Hum. Reprod. 15: 1086-1091.